TCDA - Tricida, Inc.
33.27 0.00 (0.00%)
After hours: 4:00PM EST
| Previous Close | 33.28 |
| Open | 33.30 |
| Bid | 33.26 x 1100 |
| Ask | 33.35 x 800 |
| Day's Range | 32.90 - 33.95 |
| 52 Week Range | 19.43 - 44.30 |
| Volume | 231,678 |
| Avg. Volume | 317,341 |
| Market Cap | 1.657B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Tricida to Present at the 38th Annual J. P. Morgan Healthcare Conference
Tricida to Present at the 38th Annual J. P. Morgan Healthcare Conference
- Business Wire
Tricida Announces Hiring of Elizabeth Faust, Ph.D., as Senior Vice President of Medical Affairs
Tricida, Inc. (TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), today announced the hiring of Elizabeth Faust, Ph.D., as Senior Vice President of Medical Affairs. Dr. Faust, who initially joined Tricida as a consultant in September 2019, will lead the strategic development and implementation of Tricida’s medical education, publications and disease awareness activities as the company prepares for the potential launch of veverimer in 2020.
- Business Wire
Tricida to Present at the Evercore Annual Global Healthcare Conference
Tricida, Inc. (TCDA) today announced that it will present at the Evercore ISI 2nd Annual Health Care Conference on Tuesday, December 3, 2019 at 5:00 am PT / 8 am ET. Gerrit Klaerner, Ph.D., Tricida’s Founder, President and Chief Executive Officer, will provide a company overview, business update and progress on the company’s key initiatives. Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD).
- Business Wire
Tricida Announces Third Quarter 2019 Financial Results
FDA Accepts New Drug Application for Veverimer
- Business Wire
Tricida Announces FDA Acceptance of New Drug Application for Veverimer
Tricida, Inc. (TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for veverimer under the Accelerated Approval Program. In its correspondence, FDA also stated that no filing review issues were identified.
- Business Wire
Tricida to Report Third Quarter Financial Results and Host Conference Call and Webcast on Thursday, November 14, 2019
Tricida, Inc. today announced that it will report its third quarter 2019 financial results after the close of market on Thursday, November 14, 2019. Tricida will host a conference call and webcast at 4:30 pm Eastern Time to discuss its financial results and business progress.
- Business Wire
Tricida to Host Investor Day on October 15, 2019
Tricida, Inc. (TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that it will host its inaugural Investor Day on October 15, 2019 from 8:30 a.m. to 11:30 a.m. Eastern Time in New York, NY. The Tricida management team will provide a comprehensive overview of the Company’s commercialization strategy and market opportunity for veverimer in the treatment of metabolic acidosis in patients with CKD.
- Business Wire
Tricida Announces Multiple Data Presentations on Metabolic Acidosis to be Given at ASN Kidney Week 2019
Tricida, Inc. , a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer , a non-absorbed, orally-dosed polymer designed to treat metabolic acidosis in patients with chronic kidney disease , announced today multiple presentations on metabolic acidosis that will be given at the upcoming American Society of Nephrology Kidney Week 2019 meeting taking place ...
- Business Wire
Tricida Announces Publication of Positive Long-Term Phase 3 Clinical Trial Results of Veverimer (TRC101) in The Lancet
Tricida, Inc. (TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced that The Lancet published online detailed results from its long-term, Phase 3, multicenter, parallel, randomized, blinded, placebo-controlled trial, TRCA-301E, in 196 patients with CKD and metabolic acidosis. “This new data highlights the value of treating metabolic acidosis in patients with CKD,” said Donald E. Wesson, M.D., M.B.A., Professor of Medicine at Texas A&M Health Science Center College of Medicine in Dallas, TX, lead investigator of the study and primary author of The Lancet paper.
- Business Wire
Tricida to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
Tricida, Inc. (TCDA) today announced that it will present at the Goldman Sachs 40th Annual Health Care Conference on Wednesday, June 12, 2019 at 10:00 am PT. Gerrit Klaerner, Tricida’s Founder, President and Chief Executive Officer, will provide a company overview, business update and progress on the company’s key initiatives. Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD).
- Business Wire
Tricida Announces First Quarter 2019 Financial Results
Webcast Today at 4:30 pm Eastern Time
- Business Wire
Tricida to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast on Wednesday, May 8, 2019
Tricida, Inc. (TCDA) today announced that it will report its first quarter 2019 financial results after the close of market on Wednesday, May 8, 2019. Tricida will host a conference call and webcast at 4:30 pm Eastern Time to discuss its financial results and business progress.
- Business Wire
Tricida Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Tricida, Inc. today announced the closing of its previously announced public offering of 6,440,000 shares of its common stock at a public offering price of $36.00 per share, which includes the exercise in full by the underwriters of their option to purchase 840,000 additional shares of common stock for total gross proceeds of approximately $231.8 million, before deducting underwriting discounts and ...
- Business Wire
Tricida Announces Pricing of Public Offering of Common Stock
Tricida, Inc. today announced the pricing of its public offering of 5,600,000 shares of its common stock at a public offering price of $36.00 per share for total gross proceeds of $201.6 million, before deducting underwriting discounts and commissions and other offering expenses payable by Tricida.
- Business Wire
Tricida Announces Proposed Public Offering of Common Stock
Tricida, Inc. (TCDA) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. All of the shares in the offering will be sold by Tricida. In addition, Tricida expects to grant the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock in the offering.
- Business Wire
Tricida Announces Positive Results From Long-Term Clinical Trial of TRC101 in Patients With CKD and Metabolic Acidosis
Tricida, Inc. (TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101 (veverimer), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today results from its blinded, randomized, placebo-controlled, multicenter clinical trial, TRCA-301E, in 196 CKD patients with metabolic acidosis. TRC101 represents a first-in-class drug candidate for the treatment of metabolic acidosis, a chronic condition commonly caused by CKD that is believed to accelerate the progression of CKD, increase the risk of muscle wasting and cause the loss of bone density.
- Business Wire
Tricida Announces $200 Million Debt Facility With Hercules Capital
Tricida, Inc. (TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate TRC101 (veverimer), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that it has entered into an amendment to its existing debt facility with Hercules Capital, Inc. (HTGC), a leader in customizing debt financing for companies in the life sciences and technology-related markets. Tricida originally entered into a $100 million debt facility with Hercules Capital in February 2018.
- Business Wire
Tricida Announces Fourth Quarter and Full-Year 2018 Financial Results
Webcast Today at 8:00 am Eastern Time
- ACCESSWIRE
Tricida Inc to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 28, 2019 / Tricida Inc (NASDAQ: TCDA ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 28, 2019 at 8:00 AM Eastern ...
- Business Wire
Tricida to Report Long-Term Clinical Trial Results for TRC101 in CKD Patients with Metabolic Acidosis and Host Conference Call and Webcast on Thursday, March 28, 2019
Tricida, Inc. (TCDA) today announced that it will report results from its blinded, 40-week extension trial, TRCA-301E, tomorrow morning at 7:15 am Eastern Time. Tricida will host a conference call and webcast at 8:00 am Eastern Time to discuss the TRCA-301E clinical trial results and its financial results and other business progress.
- Business Wire
Tricida Announces Publication of Positive TRC101 Pivotal Trial Results in The Lancet
Tricida, Inc., (TCDA) a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101 (veverimer), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced that The Lancet published online detailed results from its Phase 3, multicenter, parallel, randomized, double-blind, placebo-controlled trial, TRCA-301, in 217 patients with CKD and metabolic acidosis. “TRC101 substantially increased blood bicarbonate levels in the TRCA-301 trial,” said Donald E. Wesson, M.D., M.B.A., Professor of Medicine at Texas A&M Health Sciences Center College of Medicine in Dallas, TX, lead investigator of the study and primary author of The Lancet paper.